{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:57:20Z","timestamp":1780617440811,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,7]]},"DOI":"10.7759\/cureus.26648","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T01:58:50Z","timestamp":1657245530000},"source":"Crossref","is-referenced-by-count":3,"title":["Larotrectinib in Mismatch-Repair-Deficient TRK Fusion-Positive Metastatic Colon Cancer After Progression on Immunotherapy"],"prefix":"10.7759","author":[{"given":"Pashtoon M","family":"Kasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaz Khan","family":"Afghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew M","family":"Bellizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos HF","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel RL","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021, 71:7-33. 10.3322\/caac.21654","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele F","year":"2020","unstructured":"Mosele F, Remon J, Mateo J, et al.. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020, 31:1491-505. 10.1016\/j.annonc.2020.07.014","journal-title":"Ann Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth AD","year":"2010","unstructured":"Roth AD, Tejpar S, Delorenzi M, et al.. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010, 28:466-74. 10.1200\/JCO.2009.23.3452","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604867","article-title":"Deficient mismatch repair system in patients with sporadic advanced colorectal cancer","volume":"100","author":"Koopman M","year":"2009","unstructured":"Koopman M, Kortman GA, Mekenkamp L, et al.. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009, 100:266-73. 10.1038\/sj.bjc.6604867","journal-title":"Br J Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0332","article-title":"Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies","volume":"20","author":"Venderbosch S","year":"2014","unstructured":"Venderbosch S, Nagtegaal ID, Maughan TS, et al.. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014, 20:5322-30. 10.1158\/1078-0432.CCR-14-0332","journal-title":"Clin Cancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu499","article-title":"Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial","volume":"26","author":"Klingbiel D","year":"2015","unstructured":"Klingbiel D, Saridaki Z, Roth AD, Bosman FT, Delorenzi M, Tejpar S. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol. 2015, 26:126-32. 10.1093\/annonc\/mdu499","journal-title":"Ann Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman MJ","year":"2017","unstructured":"Overman MJ, McDermott R, Leach JL, et al.. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017, 18:1182-91. 10.1016\/S1470-2045(17)30422-9","journal-title":"Lancet Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02107","article-title":"Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164","volume":"38","author":"Le DT","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, et al.. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020, 38:11-9. 10.1200\/JCO.19.02107","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman MJ","year":"2018","unstructured":"Overman MJ, Lonardi S, Wong KY, et al.. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018, 36:773-9. 10.1200\/JCO.2017.76.9901","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2771","article-title":"FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors","volume":"27","author":"Marcus L","year":"2021","unstructured":"Marcus L, Donoghue M, Aungst S, et al.. FDA approval summary: entrectinib for the treatment of NTRK gene fusion solid tumors. Clin Cancer Res. 2021, 27:928-32. 10.1158\/1078-0432.CCR-20-2771","journal-title":"Clin Cancer Res"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0327","article-title":"FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors","volume":"27","author":"Marcus L","year":"2021","unstructured":"Marcus L, Fashoyin-Aje LA, Donoghue M, et al.. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid tumors. Clin Cancer Res. 2021, 27:4685-9. 10.1158\/1078-0432.CCR-21-0327","journal-title":"Clin Cancer Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-4070","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus L","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019, 25:3753-8. 10.1158\/1078-0432.CCR-18-4070","journal-title":"Clin Cancer Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio F","year":"2017","unstructured":"Pietrantonio F, Di Nicolantonio F, Schrock AB, et al.. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J Natl Cancer Inst. 2017, 109:10.1093\/jnci\/djx089","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-14-0765","article-title":"TRKing down an old oncogene in a new era of targeted therapy","volume":"5","author":"Vaishnavi A","year":"2015","unstructured":"Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 2015, 5:25-34. 10.1158\/2159-8290.CD-14-0765","journal-title":"Cancer Discov"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura R","year":"2018","unstructured":"Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics. JCO Precis Oncol. 2018, 2018:10.1200\/PO.18.00183","journal-title":"JCO Precis Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with NTRK gene fusions","volume":"32","author":"Gatalica Z","year":"2019","unstructured":"Gatalica Z, Xiu J, Swensen J, Vranic S. Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2019, 32:147-53. 10.1038\/s41379-018-0118-3","journal-title":"Mod Pathol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-18-3126","article-title":"Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions","volume":"79","author":"Cocco E","year":"2019","unstructured":"Cocco E, Benhamida J, Middha S, et al.. Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF\/KRAS are enriched for targetable kinase fusions. Cancer Res. 2019, 79:1047-53. 10.1158\/0008-5472.CAN-18-3126","journal-title":"Cancer Res"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215319","article-title":"The landscape of actionable gene fusions in colorectal cancer","volume":"20","author":"Pagani F","year":"2019","unstructured":"Pagani F, Randon G, Guarini V, et al.. The landscape of actionable gene fusions in colorectal cancer. Int J Mol Sci. 2019, 20:10.3390\/ijms20215319","journal-title":"Int J Mol Sci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-021-00206-y","article-title":"Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population","volume":"5","author":"Westphalen CB","year":"2021","unstructured":"Westphalen CB, Krebs MG, Le Tourneau C, et al.. Genomic context of NTRK1\/2\/3 fusion-positive tumours from a large real-world population. NPJ Precis Oncol. 2021, 5:69. 10.1038\/s41698-021-00206-y","journal-title":"NPJ Precis Oncol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability-high advanced colorectal cancer","volume":"383","author":"Andr\u00e9 T","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, et al.. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020, 383:2207-18. 10.1056\/NEJMoa2017699","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong DS","year":"2020","unstructured":"Hong DS, DuBois SG, Kummar S, et al.. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials. Lancet Oncol. 2020, 21:531-40. 10.1016\/S1470-2045(19)30856-3","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1200\/PO.19.00274","article-title":"Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer","volume":"3","author":"Gutierrez ME","year":"2019","unstructured":"Gutierrez ME, Price KS, Lanman RB, et al.. Genomic profiling for KRAS, NRAS, BRAF, microsatellite instability, and mismatch repair deficiency among patients with metastatic colon cancer. JCO Precis Oncol. 2019, 3:10.1200\/PO.19.00274","journal-title":"JCO Precis Oncol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8111777","article-title":"Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook","volume":"8","author":"M\u00f6hn N","year":"2019","unstructured":"M\u00f6hn N, Beutel G, Gutzmer R, Ivanyi P, Satzger I, Skripuletz T. Neurological immune related adverse events associated with nivolumab, ipilimumab, and pembrolizumab therapy-review of the literature and future outlook. J Clin Med. 2019, 8:10.3390\/jcm8111777","journal-title":"J Clin Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/99774-larotrectinib-in-mismatch-repair-deficient-trk-fusion-positive-metastatic-colon-cancer-after-progression-on-immunotherapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:39:58Z","timestamp":1707507598000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/99774-larotrectinib-in-mismatch-repair-deficient-trk-fusion-positive-metastatic-colon-cancer-after-progression-on-immunotherapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,7]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.26648","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7,7]]}}}